Ipsen S.A./€IPN
06:30
10:10
13:45
17:25
21:00
1D1W1MYTD1Y5YMAX
About Ipsen S.A.
Ipsen S.A. is a global biopharmaceutical company headquartered in Boulogne-Billancourt, France. The company focuses on the development and commercialization of innovative medicines in targeted therapeutic areas such as oncology, neuroscience, and rare diseases. Ipsen's key products include Somatuline, a treatment for neuroendocrine tumors and acromegaly, and Dysport, used for movement disorders and aesthetic indications. Founded in 1929 by Henri Beaufour, Ipsen has since expanded its presence worldwide, with a strategic emphasis on specialty care and the development of differentiated products. The company leverages its scientific expertise and research capabilities to sustain its competitive position in the biopharmaceutical industry.
Ticker
€IPN
Sector
Primary listing
PAR
Employees
5,358
Headquarters
Website
Ipsen S.A. Metrics
BasicAdvanced
€10B
23.77
€5.37
0.19
€1.40
1.10%
Price and volume
Market cap
€10B
Beta
0.19
52-week high
€124.80
52-week low
€86.78
Average daily volume
30K
Dividend rate
€1.40
Financial strength
Current ratio
1.984
Quick ratio
1.596
Long term debt to equity
19.811
Total debt to equity
20.237
Dividend payout ratio (TTM)
25.90%
Interest coverage (TTM)
30.61%
Profitability
EBITDA (TTM)
1,333
Gross margin (TTM)
83.32%
Net profit margin (TTM)
11.91%
Operating margin (TTM)
27.27%
Effective tax rate (TTM)
20.64%
Revenue per employee (TTM)
€700,000
Management effectiveness
Return on assets (TTM)
9.58%
Return on equity (TTM)
10.89%
Valuation
Price to earnings (TTM)
23.773
Price to revenue (TTM)
2.808
Price to book
2.48
Price to tangible book (TTM)
7.86
Price to free cash flow (TTM)
17.749
Free cash flow yield (TTM)
5.63%
Free cash flow per share (TTM)
7.195
Dividend yield (TTM)
1.10%
Forward dividend yield
1.10%
Growth
Revenue change (TTM)
9.45%
Earnings per share change (TTM)
-34.09%
3-year revenue growth (CAGR)
8.42%
10-year revenue growth (CAGR)
10.26%
3-year earnings per share growth (CAGR)
-15.39%
10-year earnings per share growth (CAGR)
12.24%
3-year dividend per share growth (CAGR)
5.27%
10-year dividend per share growth (CAGR)
5.12%
Bulls say / Bears say
Ipsen reported Q2 2025 sales of €901 million, up 8% year-on-year, with core EPS rising 27% driven by rare disease products, prompting an upgrade of full-year guidance to over 7% CER sales growth and over 32% core operating margin.
On 23 July 2025, the European Commission approved Cabometyx for previously treated advanced neuroendocrine tumors, marking its sixth indication and strengthening Ipsen’s oncology franchise.
Ipsen agreed to acquire ImCheck Therapeutics for an upfront €350 million (total consideration up to €1 billion), adding ICT01, a first-in-class anti-BTN3A monoclonal antibody for AML with orphan designations, strengthening its oncology pipeline.
Ipsen warned that increased competition for Somatuline could weigh on second-half sales, reflecting potential revenue erosion from generics in the US and Europe.
Adverse currency movements are expected to reduce Ipsen’s reported total sales by around 2% in H1 2025, potentially dampening organic growth momentum.
Oncology portfolio headwinds surfaced as Cabometyx and Decapeptyl sales remained flat in Q2 2025 due to competitive pressure, signaling potential stagnation in a core revenue segment.
Data summarised monthly by Lightyear AI. Last updated on 1 Nov 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Ipsen S.A. stock?
Ipsen S.A. (IPN) has a market cap of €10B as of November 12, 2025.
What is the P/E ratio for Ipsen S.A. stock?
The price to earnings (P/E) ratio for Ipsen S.A. (IPN) stock is 23.77 as of November 12, 2025.
Does Ipsen S.A. stock pay dividends?
Yes, the Ipsen S.A. (IPN) stock pays dividends to shareholders. As of November 12, 2025, the dividend rate is €1.4 and the yield is 1.1%. Ipsen S.A. has a payout ratio of 25.9% on a trailing twelve-month basis.
When is the next Ipsen S.A. dividend payment date?
The next Ipsen S.A. (IPN) dividend payment date is unconfirmed.
What is the beta indicator for Ipsen S.A.?
Ipsen S.A. (IPN) has a beta rating of 0.19. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.